Applications
Allergic and Inflammatory Diseases
Mast cell hyperactivation plays a causal role in various allergic and inflammatory diseases. Many of these diseases have no or very limited treatment alternatives, which are often associated with severe side effects.
With membrane intervention therapeutics, JADO introduces a new mode-of-action for the treatment of moderate to severe allergic diseases. These compounds are positioned to challenge steroids and immunosuppressive agents in the treatment of topical and systemic allergic as well as inflammatory diseases.
The incidence of allergy and inflammatory disease is rising dramatically. More than one million Americans suffer from atopic dermatitis or urticaria (hives), forty million from allergic rhinitis (hay fever) and ten million from asthma.
In the US alone, $1 billion is spent on antihistamines each year and the global asthma/COPD market is approximately $13 billion. Many of the currently available therapies are inadequate and the patients’ quality of life is severely reduced. Thus, there is strong demand for therapies with improved safety profiles and new modes-of-action to supplement existing therapies or to establish a new line of defense.
JADO is conducting phase IIa studies with its first-in-class allergy lead candidate, miltefosine, in therapy of dermal and systemic diseases.
|
|||||
